Central Pain Syndrome Management Market

Demand for central pain syndrome management will increase through 2036, with anticonvulsants at 57.3% of the drug class segment in 2026. The market was valued at USD 66.10 billion in 2025 and is expected to be worth USD 146.45 billion by 2036, creating an incremental opportunity of USD 75.39 billion.